quinazolines has been researched along with ponatinib in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adkins, J; Aldrich, J; Asmann, Y; Baker, A; Barr Fritcher, EG; Barrett, MT; Bhavsar, JD; Bible, KC; Block, M; Borad, MJ; Bryce, AH; Carpten, JD; Champion, MD; Cherni, I; Christoforides, A; Collins, JM; Condjella, RM; Craig, DW; Egan, JB; Fonseca, R; Han, H; Harris, P; Hunt, K; Izatt, T; Kipp, BR; Klee, EW; Kocher, JP; Kurdoglu, A; Lazaridis, KN; Liang, WS; Lobello, J; Mastrian, SD; McCullough, AE; McDonald, J; McWilliams, RR; Middha, S; Nair, AA; Nasser, S; Oliver, GR; Patel, MD; Phillips, L; Placek, P; Reiman, R; Schahl, K; Silva, AC; Stewart, AK; Von Hoff, D; Watanabe, AT; Young, SW | 1 |
| Cao, Y; Du, P; Kim, HJ; Lee, HJ; Settleman, J; Zhuang, G | 1 |
| Airhart, S; Bult, C; Davis, RR; de Vere White, RW; Gandara, DR; Ghosh, PM; Gill, P; Keck, J; Lin, TY; Liu, E; Pan, CX; Tepper, CG; Zhang, H | 1 |
| Ohyashiki, K; Okabe, S; Sakuta, J; Tanaka, Y; Tauchi, T | 1 |
| Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
| Usui, N | 1 |
| Lambrecht, AM; Larocque, EA; Naganna, N; Opoku-Temeng, C; Sintim, HO | 1 |
1 review(s) available for quinazolines and ponatinib
| Article | Year |
|---|---|
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
1 trial(s) available for quinazolines and ponatinib
| Article | Year |
|---|---|
Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.
Topics: Animals; Female; Heterografts; Humans; Imidazoles; Lapatinib; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Pyridazines; Quinazolines; Quinolines; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
5 other study(ies) available for quinazolines and ponatinib
| Article | Year |
|---|---|
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Genome, Human; Humans; Imidazoles; Indazoles; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Transcriptome | 2014 |
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Interleukin-6; Janus Kinase 1; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, SCID; Mutation; Nitriles; Oncogenes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; ras Proteins; Receptors, Fibroblast Growth Factor; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2014 |
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasms, Experimental; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinazolines | 2016 |
JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
Topics: Algorithms; Aniline Compounds; Antineoplastic Agents; Aspirin; Blood Transfusion; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imidazoles; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Nitriles; Phlebotomy; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; Quinolines; Risk | 2017 |
Alkynylnicotinamide-Based Compounds as ABL1 Inhibitors with Potent Activities against Drug-Resistant CML Harboring ABL1(T315I) Mutant Kinase.
Topics: Alkynes; Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Imatinib Mesylate; Imidazoles; Isoquinolines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Docking Simulation; Naphthyridines; Niacinamide; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyridazines; Quinazolines | 2018 |